MedTrace Logo

Safety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors

NCT06781983 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 145

Last updated 2026-01-07

No results posted yet for this study

Summary

This is a first-in-human, open-label, multicenter, Phase 1 study to evaluate the safety, tolerability and preliminary efficacy of IPH4502 and to determine the recommended Phase 2 dose (RP2D) in advanced solid tumors that are known to express Nectin-4

Conditions

  • Advanced or Metastatic Solid Tumors

Interventions

DRUG

IPH4502

Part 1 (dose escalation) and Part 2 (dose optimization)

Sponsors & Collaborators

  • Innate Pharma

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-01-24
Primary Completion
2028-04-30
Completion
2029-04-30
FDA Drug
Yes

Countries

  • United States
  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06781983 on ClinicalTrials.gov